Boehringer merges can­cer vac­cine and on­colyt­ic virus teams; Dan­tari sells off as­sets

Plus, news about Madrona and Ab­dera:

Boehringer In­gel­heim com­bines two can­cer units: The drug­mak­er is merg­ing its can­cer vac­cine unit AMAL Ther­a­peu­tics …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.